ALK and non-small cell lung carcinoma: While vaccine therapy trials in NSCLC have so far failed to show significant clinical benefit, the demonstration of enhanced immune response in these trials suggests that an ALK-directed vaccine therapy could have more degree of clinical efficacy in combination with checkpoint inhibitors.